Completed PHASE3 INTERVENTIONAL 1-arm NCT01838941

Betaine and Peroxisome Biogenesis Disorders

A Pilot, Open Label Trial Assessing the Safety and Efficacy of Betaine in Children With Peroxisome Biogenesis Disorders.

Sponsor: Children's Hospital and Medical Center, Omaha, Nebraska

Conditions Peroxisome Biogenesis Disorders

Interventions Betaine

Updated 9 times since 2017 Last updated: May 20, 2016 Started: Mar 31, 2013 Primary completion: Jan 31, 2015 Completion: Jun 30, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Peroxisome Biogenesis Disorders, this trial is completed. The trial is conducted by Children's Hospital and Medical Center, Omaha, Nebraska and has accumulated 9 data snapshots since 2013. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Dec 2021 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — Dec 2021 [monthly]

Completed PHASE3
Oct 2019 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 4 earlier versions

Oct 2018 — Oct 2019 [monthly]

Completed PHASE3
Jun 2018 — Oct 2018 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Mar 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Children's Hospital and Medical Center, Omaha, Nebraska
McGill University Health Centre/Research Institute of the McGill University Health Centre

Data source: McGill University Health Centre/Research Institute of the McGill University Health Centre

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Montreal, Canada